tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Pharmacol. Exp. Ther. (1)
- Am. J. Physiol. Renal Physiol. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Manuyakorn W et al. | In vitro cytokine changes after pediatric liver transplantation. | 2015 | Asian Pac. J. Allergy Immunol. | pmid:25840634 |
| Li T et al. | Effect of FK506 nanospheres on regeneration of allogeneic nerve after transplant. | 2014 | Asian Pac J Trop Med | pmid:25066398 |
| Dai YJ et al. | Effect of pharmacological intervention on MIP-1α, MIP-1β and MCP-1 expression in patients with psoriasis vulgaris. | 2014 | Asian Pac J Trop Med | pmid:25063291 |
| Ogita K et al. | Renal tubular acidosis secondary to FK506 in living donor liver transplantation: a case report. | 2003 | Asian J Surg | pmid:14530108 |
| Cacciarelli TV et al. | Influence of the timing of FK 506 (Tacrolimus) administration on recovery of renal function from warm ischemic injury in rats. | 1994 Oct-Dec | ASAIO J. | pmid:7532042 |
| Tsubo T et al. | Elimination of FK-506 by continuous hemodiafiltration in a liver transplant patient. | 1997 Jul-Aug | ASAIO J. | pmid:9242954 |
| Imanishi Y et al. | Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation. | 2011 | Arzneimittelforschung | pmid:21528645 |
| Takayama T et al. | Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice. | 2010 | Arzneimittelforschung | pmid:20533766 |
| Lainesse A et al. | Bioequivalence studies of tacrolimus capsule under fasting and fed conditions in healthy male and female subjects. | 2008 | Arzneimittelforschung | pmid:18589558 |
| Haehner T et al. | Drug-drug interactions evaluated by a highly active reconstituted native human cytochrome P4503A4 and human NADPH-cytochrome P450 reductase system. | 2004 | Arzneimittelforschung | pmid:14979613 |
| MarcelÃn-Jiménez G et al. | Development of an ultra-performance liquid chromatography technique coupled with mass spectrometry for the measurement of tacrolimus in micro-samples of whole blood, and its application on a pharmacokiinetic trial. | 2007 | Arzneimittelforschung | pmid:18074760 |
| Iwasaki K et al. | Effect of repeated oral doses of a novel immunosuppressive macrolide lactone on hepatic mixed-function oxidase system in the rat. Comparative study with ciclosporin. | 1992 | Arzneimittelforschung | pmid:1379812 |
| Dawson S et al. | UCLA liver transplantation: analysis of immunological factors affecting outcome. | 1996 | Artif Organs | pmid:8896726 |
| Kashu Y et al. | Prolongation of rat liver graft survival by splenectomy combined with low dose FK506 therapy. | 1996 | Artif Organs | pmid:8896731 |
| Ohshima S et al. | Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors. | 1996 | Artif Organs | pmid:8896734 |
| Wada Y et al. | BCX-34: a novel T-cell selective immunosuppressant: purine nucleoside phosphorylase (PNP) inhibitor. | 1996 | Artif Organs | pmid:8853794 |
| Haisheng H et al. | Assessment of nerve regeneration across nerve allografts treated with tacrolimus. | 2008 | Artif Cells Blood Substit Immobil Biotechnol | pmid:18925465 |
| van der Windt AE et al. | Inhibiting calcineurin activity under physiologic tonicity elevates anabolic but suppresses catabolic chondrocyte markers. | 2012 | Arthritis Rheum. | pmid:22231955 |
| Suzuki N et al. | In vivo mechanisms for the inhibition of T lymphocyte activation by long-term therapy with tacrolimus (FK-506): experience in patients with Behçet's disease. | 1997 | Arthritis Rheum. | pmid:9182928 |
| de Paulis A et al. | Human synovial mast cells. II. Heterogeneity of the pharmacologic effects of antiinflammatory and immunosuppressive drugs. | 1997 | Arthritis Rheum. | pmid:9082935 |
| Cho ML et al. | Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes. | 2002 | Arthritis Rheum. | pmid:11817607 |
| Kremer JM et al. | Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. | 2003 | Arthritis Rheum. | pmid:14558080 |
| Asano Y et al. | Differential effects of the immunosuppressant FK-506 on human alpha2(I) collagen gene expression and transforming growth factor beta signaling in normal and scleroderma fibroblasts. | 2005 | Arthritis Rheum. | pmid:15818662 |
| Wilkes MR et al. | Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. | 2005 | Arthritis Rheum. | pmid:16052580 |
| Stone JH et al. | Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. | 1998 | Arthritis Rheum. | pmid:9704643 |
| Yocum DE et al. | Efficacy and safety of tacrolimus in patients with rheumatoid arthritis: a double-blind trial. | 2003 | Arthritis Rheum. | pmid:14673984 |
| Furst DE et al. | Efficacy of tacrolimus in rheumatoid arthritis patients who have been treated unsuccessfully with methotrexate: a six-month, double-blind, randomized, dose-ranging study. | 2002 | Arthritis Rheum. | pmid:12209503 |
| Cho ML et al. | Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts. | 2002 | Arthritis Rheum. | pmid:12115224 |
| Parker CT and Rennie T | Failure to report previously used drugs and dosages in pharmaceutical company-sponsored rheumatoid arthritis trials: comment on the article by Yocum et al. | 2004 | Arthritis Rheum. | pmid:15457479 |
| Migita K et al. | Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tacrolimus. | 2015 | Arthritis Res. Ther. | pmid:26036592 |
| Choe JY et al. | Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes. | 2013 | Arthritis Res. Ther. | pmid:23406906 |
| Long C et al. | Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. | 2007 | Arterioscler. Thromb. Vasc. Biol. | pmid:17478757 |
| Ikezoe T et al. | Thrombomodulin protects endothelial cells from a calcineurin inhibitor-induced cytotoxicity by upregulation of extracellular signal-regulated kinase/myeloid leukemia cell-1 signaling. | 2012 | Arterioscler. Thromb. Vasc. Biol. | pmid:22796578 |
| Murakami R et al. | Cyclosporin A enhances interleukin-8 expression by inducing activator protein-1 in human aortic smooth muscle cells. | 2003 | Arterioscler. Thromb. Vasc. Biol. | pmid:12958044 |
| Vindis C et al. | Two distinct calcium-dependent mitochondrial pathways are involved in oxidized LDL-induced apoptosis. | 2005 | Arterioscler. Thromb. Vasc. Biol. | pmid:15618541 |
| Lasa J and Olivera P | EFFICACY OF TACROLIMUS FOR INDUCTION OF REMISSION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS. | Arq Gastroenterol | pmid:28327826 | |
| Müller EG et al. | Tacrolimus eye drops as monotherapy for vernal keratoconjunctivitis: a randomized controlled trial. | 2017 | Arq Bras Oftalmol | pmid:28832739 |
| Liendo VL et al. | Topical tacrolimus for the treatment of severe allergic keratoconjunctivitis in children. | Arq Bras Oftalmol | pmid:28954018 | |
| Zulim LFDC et al. | Comparison of the efficacy of 0.03% tacrolimus eye drops diluted in olive oil and linseed oil for the treatment of keratoconjunctivitis sicca in dogs. | Arq Bras Oftalmol | pmid:29995121 | |
| Carvalho CS et al. | [Fibroblasts from recurrent pterygium and normal Tenon's capsule exposed to tacrolimus (FK-506)]. | 2007 Mar-Apr | Arq Bras Oftalmol | pmid:17589693 |
| Nakamura K | [Treatment of atopic dermatitis]. | 2009 | Arerugi | pmid:19901507 |
| Saeki H | [Brief commentary on guidelines for the management of atopic dermatitis 2012 -the point of drug treatment]. | 2013 | Arerugi | pmid:24608647 |
| Ochiai T | [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. | 1992 | Arerugi | pmid:1374229 |
| Teraki Y | [Atopic dermatitis in pregnancy]. | 2014 | Arerugi | pmid:24714179 |
| Ebihara N | [New strategy in the treatment of vernal keratoconjunctivitis by calcineurin inhibitor eye drops]. | 2010 | Arerugi | pmid:21119297 |
| Akutsu I et al. | [Inhibitory effects of cyclosporin A and FK-506 on eosinophil chemotactic factor activity in culture supernatants of mononuclear cells from asthmatics]. | 1992 | Arerugi | pmid:1280086 |
| Yamamoto S | [Guidelines for the management of atopic dermatitis 2006]. | 2008 | Arerugi | pmid:19052504 |
| Akutsu I et al. | [Inhibitory effect of inhaled FK-506 on increased bronchial responsiveness and eosinophil infiltration in the airway mucosa]. | 1992 | Arerugi | pmid:1377905 |
| Hossain M et al. | Effects of various drugs (staurosporine, herbimycin A, ketotifen, theophylline, FK506 and cyclosporin A) on eosinophil viability. | 1994 | Arerugi | pmid:7520689 |
| Takehara K | [Treatment of juvenile atopic dermatitis]. | 2010 | Arerugi | pmid:21212728 |
| Akutsu I et al. | [Inhibitory effect of FK-506 on the development of late asthmatic response and on the increased bronchial responsiveness]. | 1990 | Arerugi | pmid:1705791 |
| Ohtsuki M | [Tacrolimus ointment for the treatment of atopic dermatitis]. | 2009 | Arerugi | pmid:19487830 |
| Nishimoto K et al. | [Case of organizing pneumonia associated with sweet's syndrome]. | 2014 | Arerugi | pmid:25163580 |
| Briggs CJ et al. | Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1. | 1999 | Arch. Virol. | pmid:10603169 |
| Minder D et al. | Immunophilins and HIV-1 infection. | 2002 | Arch. Virol. | pmid:12181673 |
| Ellouk-Achard S et al. | Implication of CYP 3A in the toxicity of cyclosporin G (CsG), cyclosporin A (CsA) and FK506 on rat hepatocytes in primary culture. | 1997 | Arch. Toxicol. | pmid:9209689 |
| Aam BB and Fonnum F | Carbon black particles increase reactive oxygen species formation in rat alveolar macrophages in vitro. | 2007 | Arch. Toxicol. | pmid:17119925 |
| Kafert-Kasting S et al. | Safety assessment of intraportal liver cell application in New Zealand white rabbits under GLP conditions. | 2012 | Arch. Toxicol. | pmid:22532025 |
| Massicot F et al. | Modulation of energy status and cytotoxicity induced by FK506 and cyclosporin A in a renal epithelial cell line. | 1997 | Arch. Toxicol. | pmid:9248632 |
| Kimura Y et al. | Profiling the immunotoxicity of chemicals based on in vitro evaluation by a combination of the Multi-ImmunoTox assay and the IL-8 Luc assay. | 2018 | Arch. Toxicol. | pmid:29594315 |
| Vandenbussche C et al. | Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. | 2018 | Arch. Toxicol. | pmid:29362864 |
| Ellouk-Achard S et al. | FK506 (Tacrolimus) decreases the cytotoxicity of cyclosporin A in rat hepatocytes in primary culture: implication of CYP3A induction. | 1998 | Arch. Toxicol. | pmid:9630010 |
| Schaap MM et al. | A novel toxicogenomics-based approach to categorize (non-)genotoxic carcinogens. | 2015 | Arch. Toxicol. | pmid:25270620 |
| Chung Y and Cho H | Preparation of highly water soluble tacrolimus derivatives: poly(ethylene glycol) esters as potential prodrugs. | 2004 | Arch. Pharm. Res. | pmid:15460452 |
| Kwon M et al. | Bioequivalence of tacrolimus formulations with different dynamic solubility and in-vitro dissolution profiles. | 2015 | Arch. Pharm. Res. | pmid:24627339 |
| Park YJ et al. | Physicochemical characterization of tacrolimus-loaded solid dispersion with sodium carboxylmethyl cellulose and sodium lauryl sulfate. | 2009 | Arch. Pharm. Res. | pmid:19557367 |
| Seo YG et al. | Preparation and pharmaceutical evaluation of new tacrolimus-loaded solid self-emulsifying drug delivery system. | 2015 | Arch. Pharm. Res. | pmid:25134927 |
| Park JS et al. | A rapid and sensitive method to determine tacrolimus in rat whole blood using liquid-liquid extraction with mild temperature ultrasonication and LC-MS/MS. | 2016 | Arch. Pharm. Res. | pmid:26589688 |
| Choi D and Cho H | Effect of tacrolimus derivatives on immunosuppression. | 2009 | Arch. Pharm. Res. | pmid:19407973 |
| Choi D et al. | Effects of water-soluble tacrolimus-PEG conjugate on insulin-dependent diabetes mellitus and systemic lupus erythematosus. | 2011 | Arch. Pharm. Res. | pmid:21910052 |
| Hüser N et al. | Graft preconditioning with low-dose tacrolimus (FK506) and nitric oxide inhibitor aminoguanidine (AGH) reduces ischemia/reperfusion injury after liver transplantation in the rat. | 2009 | Arch. Pharm. Res. | pmid:19280151 |
| Etzell JE and Wang E | Acquired Pelger-Huët anomaly in association with concomitant tacrolimus and mycophenolate mofetil in a liver transplant patient: a case report and review of the literature. | 2006 | Arch. Pathol. Lab. Med. | pmid:16390246 |
| DiGiuseppe JA et al. | Tacrolimus-related posttransplant lymphoproliferative disorder presenting as autoimmune hemolytic anemia. | 1996 | Arch. Pathol. Lab. Med. | pmid:8629906 |
| Steele BW et al. | A longitudinal replicate study of immunosuppressive drugs: a College of American Pathologists study. | 2003 | Arch. Pathol. Lab. Med. | pmid:12653570 |
| Wang S et al. | A fast and simple high-performance liquid chromatography/mass spectrometry method for simultaneous measurement of whole blood tacrolimus and sirolimus. | 2005 | Arch. Pathol. Lab. Med. | pmid:15859639 |
| Gorgan M et al. | Pulmonary hemorrhage with capillaritis secondary to mycophenolate mofetil in a heart-transplant patient. | 2013 | Arch. Pathol. Lab. Med. | pmid:24168511 |
| Papadea C and Lage JM | Immunosuppressants testing in transplantation. | 2004 | Arch. Pathol. Lab. Med. | pmid:15578873 |
| Linder MW and Elin RJ | Implications of methodologic bias for therapeutic drug monitoring. | 1999 | Arch. Pathol. Lab. Med. | pmid:10506447 |
| Deschler DG et al. | Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. | 1995 | Arch. Otolaryngol. Head Neck Surg. | pmid:7544136 |
| Moura Penteado LA et al. | Evaluation of the effect of tacrolimus on periodontitis induced in rats. | 2017 | Arch. Oral Biol. | pmid:28399470 |
| Gürkan A et al. | Alpha 2 integrin gene (ITGA2) polymorphism in renal transplant recipients with and without drug induced gingival overgrowth. | 2014 | Arch. Oral Biol. | pmid:24581850 |
| Gürkan A et al. | Gingival crevicular fluid transforming growth factor-beta1 in cyclosporine and tacrolimus treated renal transplant patients without gingival overgrowth. | 2008 | Arch. Oral Biol. | pmid:18342291 |
| Guimarães MR et al. | Protective effects of Tacrolimus, a calcineurin inhibitor, in experimental periodontitis in rats. | 2007 | Arch. Oral Biol. | pmid:17367747 |
| Cota LO et al. | Gingival overgrowth in cyclosporine, tacrolimus, or sirolimus-based immunosuppressive regimens and the single nucleotide IL-6 (-174 G/C) gene polymorphism. | 2010 | Arch. Oral Biol. | pmid:20430366 |
| Emingil G et al. | GCF and serum myeloperoxidase and matrix metalloproteinase-13 levels in renal transplant patients. | 2010 | Arch. Oral Biol. | pmid:20637451 |
| Türkoğlu O et al. | Are antimicrobial peptides related to cyclosporine A-induced gingival overgrowth? | 2015 | Arch. Oral Biol. | pmid:25555253 |
| Liang L et al. | Long-term outcomes of keratolimbal allograft for total limbal stem cell deficiency using combined immunosuppressive agents and correction of ocular surface deficits. | 2009 | Arch. Ophthalmol. | pmid:19901207 |
| Murphy CC et al. | Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. | 2005 | Arch. Ophthalmol. | pmid:15883282 |
| Okada AA | Noninfectious uveitis: a scarcity of randomized clinical trials. | 2005 | Arch. Ophthalmol. | pmid:15883289 |
| John SS et al. | Chronic localized fibrosing vasculitis of the eyelid. | 2009 | Arch. Ophthalmol. | pmid:19822864 |
| Orange D et al. | Cellular immune suppression in paraneoplastic neurologic syndromes targeting intracellular antigens. | 2012 | Arch. Neurol. | pmid:22566506 |
| Parashos SA et al. | Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. | 2009 | Arch. Neurol. | pmid:19597081 |
| Horne SM and Young KD | Escherichia coli and other species of the Enterobacteriaceae encode a protein similar to the family of Mip-like FK506-binding proteins. | 1995 | Arch. Microbiol. | pmid:7540828 |
| GarcÃa-Roca P et al. | CYP3A5 polymorphism in Mexican renal transplant recipients and its association with tacrolimus dosing. | 2012 | Arch. Med. Res. | pmid:22704849 |
| Saner FH et al. | Severe neurological events following liver transplantation. | 2007 | Arch. Med. Res. | pmid:17174727 |
| Lenz O and Contreras G | Treatment options for severe lupus nephritis. | 2004 Sep-Oct | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:15507877 |
| Nowaczyk M et al. | 2-Chlorodeoxyadenosine: lack of synergism with cyclosporine A and tacrolimus (FK 506). | 1995 | Arch. Immunol. Ther. Exp. (Warsz.) | pmid:8744655 |
| Campo JV et al. | Tacrolimus toxic reaction associated with the use of nefazodone: paroxetine as an alternative agent. | 1998 | Arch. Gen. Psychiatry | pmid:9819077 |
| Deckers-Kocken JM and Pasmans SG | Successful tacrolimus (FK506) therapy in a child with pyoderma gangrenosum. | 2005 | Arch. Dis. Child. | pmid:15851442 |
| Hofman T et al. | Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children. | 2006 | Arch. Dis. Child. | pmid:16798785 |